Human Immumoglobulin for Intravenous Injection Market

This product is human-plasma-derived. Although the screening and testing measures of infectious agents and viral removal and inactivation added in the manufacture process, theoretically, there is still potential risk in the transmission of some known and even unknown infectious agents.
Human Immumoglobulin for Intravenous Injection Market contains market size and forecasts of Human Immumoglobulin (PH4) for Intravenous Injection in global, including the following market information:
Global Human Immumoglobulin (PH4) for Intravenous Injection Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Human Immumoglobulin (PH4) for Intravenous Injection Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Human Immumoglobulin (PH4) for Intravenous Injection companies in 2021 (%)
The global Human Immumoglobulin (PH4) for Intravenous Injection market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
1g/20ml Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Human Immumoglobulin (PH4) for Intravenous Injection include Boya-Bio, Beijing Tiantan Biological Products, Guangdong Shuagnlin Bio-pharmacy, Weiguang Biological, Hualan Bio, CTBB, Sinopharm, Nanyue Biopharming and Shanghai RAAS. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Human Immumoglobulin (PH4) for Intravenous Injection manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Immumoglobulin (PH4) for Intravenous Injection Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Human Immumoglobulin (PH4) for Intravenous Injection Market Segment Percentages, by Type, 2021 (%)
1g/20ml
1.25g/25ml
2.5g/50ml
5g/100ml
10g/200ml
Global Human Immumoglobulin (PH4) for Intravenous Injection Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Human Immumoglobulin (PH4) for Intravenous Injection Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Others
Global Human Immumoglobulin (PH4) for Intravenous Injection Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Human Immumoglobulin (PH4) for Intravenous Injection Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Human Immumoglobulin (PH4) for Intravenous Injection revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Human Immumoglobulin (PH4) for Intravenous Injection revenues share in global market, 2021 (%)
Key companies Human Immumoglobulin (PH4) for Intravenous Injection sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Human Immumoglobulin (PH4) for Intravenous Injection sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Boya-Bio
Beijing Tiantan Biological Products
Guangdong Shuagnlin Bio-pharmacy
Weiguang Biological
Hualan Bio
CTBB
Sinopharm
Nanyue Biopharming
Shanghai RAAS